• Earlier this month, Travere Therapeutics announced that the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only approved therapy for this rare kidney disease.
• This approval, backed by the large Phase 3 DUPLEX Study and aligned with KDIGO guidelines, extends FILSPARI’s reach beyond IgA nephropathy into a second rare kidney indication and expands Travere’s addressable U.S. patient pool to more than 100,000 individuals.
• We’ll now examine how FILSPARI’s first-in-class FSGS approval, and the more than 30,000 additional U.S. patients, reshapes Travere’s investment narrative.

Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

Travere Therapeutics Investment Narrative Recap

To own Travere here, you need to believe FILSPARI can anchor a focused rare kidney franchise while the company manages its dependence on a single flagship asset. The new FSGS approval appears to reinforce, rather than redefine, the near term story by broadening FILSPARI’s reach, while the biggest risk remains execution and payer response around this expanding, REMS restricted product.

Among recent announcements, the 2025 updates on the sNDA review and REMS label modification stand out as particularly relevant, because they set expectations for the FSGS decision and ongoing liver safety monitoring before this full approval arrived. Together with the DUPLEX data, they frame how quickly FILSPARI might be adopted in real world practice and how much burden the REMS program could place on physicians and patients.

Yet, beneath the excitement around first in class status and a larger patient pool, investors still need to pay close attention to the risks tied to...

Travere Therapeutics' narrative projects $1.1 billion revenue and $289.1 million earnings by 2029. This requires 30.5% yearly revenue growth and a $339.4 million earnings increase from -$50.3 million today.

Uncover how Travere Therapeutics' forecasts yield a $42.50 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before this approval, the most bullish analysts were already assuming Travere could reach about US$1.5 billion in revenue and roughly US$576.6 million in earnings by 2029, so if you are weighing those optimistic assumptions against this new FSGS label and the possibility of near monopoly pricing power in a small population, it is worth remembering that reasonable investors can look at the same data and reach very different conclusions about what happens next.

Explore 7 other fair value estimates on Travere Therapeutics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

No Opportunity In Travere Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.